Our objective was to determine the influence of bovine growth hormone (bGH) and bovine growth hormone-releasing factor (bGRF) administration on the mRNA abundance of lipoprotein lipase (LpL) and stearoyl-CoA desaturase (SCD). Primiparous Holstein cows received bGH, bGRF, or no treatment from 118 to 181 ± 1 d postpartum. We hypothesized that bGH and bGRF treatment would increase the mRNA abundance of both SCD and LpL in the mammary gland with a corresponding reduction in adipose tissue. Milk yield significantly increased but milk fat percentage did not change as a result of bGH or bGRF treatment. Short-, medium-, and long-chain fatty acid concentrations in milk were not affected by either bGH or bGRF treatments, with the exception of a modest, but significant, increase in C16:1 and C18:1 following bGH treatment. Analysis was conducted on the genes encoding LpL (E.C. 3.3.1.34), a key enzyme involved in the uptake of fatty acids into tissues, and SCD (E.C.
Introduction
Milk fat synthesis is influenced by a number of factors, including season, stage of lactation, and diet. 412 1.14.99.5), which is the enzyme responsible for introducing ∆9 double bonds in fatty acids of 16 and 18 carbons in length. In adipose tissue, treatment with bGH and bGRF reduced the mRNA abundance of LpL to 14.6 and 25.7% respectively, of that observed for control animals. Similarly, these treatments reduced the SCD mRNA abundance to undetectable levels in adipose tissue. In mammary gland, bGH and bGRF had no significant impact on LpL mRNA abundance. Bovine GH did not significantly affect SCD mRNA abundance in the mammary gland, and bGRF reduced SCD mRNA abundance. From this study to examine the role of bGH and bGRF on the expression of the genes encoding these key lipogenic enzymes in cattle, we conclude that the increased substrate required for enhanced milk fatty acid yield may have been provided through redirection of nutrients to the mammary gland away from adipose tissue and through overall increased metabolism in the mammary gland.
Treatment with either bovine growth hormone (bGH) (Eppard et al., 1991; Hartnell et al., 1991; Lynch et al., 1992) or bovine growth hormone-releasing factor (bGRF) (Lapierre et al., 1988; Hodate et al., 1989) has increased milk yield with little or no change in milk fat percentage, thus implying increased total milk fat yield. As a tool for elucidating the mechanisms of regulation of milk fat synthesis, we examined the role of bGH and bGRF administration on milk fat synthesis. The focus of this research was on lipoprotein lipase (LpL) and stearoyl-CoA desaturase (SCD). We hypothesized that mRNA abundance of both LpL and SCD would be increased in the mammary gland and decreased in adipose tissue as a result of bGH or bGRF administration. Specifically, our objective was to determine the influence of bGH and bGRF administration on the mRNA abundance of LpL and SCD in the mammary gland and adipose tissue.
Materials and Methods

Experimental Design
The animals used in this study were part of a larger study conducted at Michigan State University. Details of the study are provided in Binelli et al. (1995) . In brief, 30 primiparous cows were assigned at random to one of 10 blocks on the basis of parturition date. Within each block, one animal was treated with continuous intravenous infusion of 29 mg/d of recombinant bGH (Somavubove, Pharmacia & Upjohn, Kalamazoo, MI), while another animal was treated with continuous intravenous infusion of 12 mg/d of recombinant bovine growth hormone-releasing factor (1-45) homoserine lactone (bGRF) (Pharmacia & Upjohn). The last animal in each block received no treatment and served as the control. The bGRF level was designed to achieve circulating GH levels similar to those caused by bGH treatment and was based on the results of Dahl et al. (1991) . Animals received treatment from 118 to 181 ± 1 d postpartum. On the final day of treatment, animals were slaughtered, and the tissue was harvested, frozen in liquid nitrogen, and stored at −70°C.
Mammary gland tissue collected from six blocks of animals was used for all analyses. Omental fat collected from four of the six blocks of animals was used for SCD analyses, and omental fat from three of the six blocks of animals was used to examine LpL. Numbers of animals tested differed because the amount of omental fat available for some of the animals was not sufficient to perform the analysis.
Quantification of Messenger RNA Abundance
Total RNA was isolated from 200 mg of mammary gland tissue and from 800 mg of omental fat tissue using TRIzol (Gibco BRL/Life Technologies, Gaithersburg, MD) following the manufacturer's instructions with some modifications. Specifically, for both mammary gland and omental fat isolations, a second 75% ethanol wash step was added to further purify the RNA. The incubation following an isopropanol addition was increased from 10 min, as per the manufacturer's recommendation, to 1 h. In addition, a 10-min centrifugation at 12,000 × g was added immediately after the homogenization step. The RNA was quantified by measuring its absorbance at 260 nm using a Gene Quant spectrophotometer (Pharmacia, Cambridge, U.K.). The quality and purity of the RNA was determined by taking the ratio of the absorbance of the sample at 260 nm:280 nm. Ribonucleic acid samples with 260:280 nm ratios of 1.8 to 2.0 were deemed of sufficient quality for analysis. The quality was confirmed by evaluating 5 µg of each sample on a 1% agarose − formaldehyde denaturing gel (1% wt/vol agarose, .66 M formaldehyde in 1× MOPS [3-(n-morpholino) propanesulfonic acid] solution) using a 1× MOPS buffer (.2 M MOPS, .05 M sodium acetate trihydrate, .01 M EDTA). Samples with a ratio of approximately 2:1 for the quantity of ethidium bromide-stained 28s:18s ribosomal RNA species that did not demonstrate any degradation were selected for further analysis.
A 2.4-kb cDNA fragment of the human LpL coding sequence in pUC19 was used to transform Eschericia coli XLI blue. A 2.6-kb cDNA fragment of the coding sequence of rat stearoyl-CoA desaturase 1 (SCD1) was subcloned into the EcoRI site of pBluescript SK, which was then used to transform E. coli XLIblue. The plasmid-insert DNA was isolated using a plasmid DNA purification kit (Sigma Chemical Company, St. Louis, MO). The LpL insert cDNA was excised from the plasmid using SalI. The SCD insert cDNA was excised from the pBluescript SK vector using EcoRI. Insert DNA was then separated from plasmid DNA on a 1.2% agarose gel and eluted from the agarose using a GeneClean kit (Bio101, Vista, CA). The purified LpL and SCD cDNA inserts were labeled using a random primer DNA labeling kit (GibcoBRL/Life Technologies) and α[ 32 P]dATP. Validation of the probes was performed with a gel of 10 to 40 µg of total RNA from adipose and mammary gland tissue along with total RNA from rat liver and mRNA-enriched RNA (poly A + ) isolated from bovine mammary gland as positive controls. This was evaluated along with an RNA molecular weight marker to confirm the loading requirements, the ability of the probes to cross-react with bovine tissue, and the size of the transcript.
In order to determine mRNA abundance of LpL and SCD, total RNA from the mammary gland and omental fat samples was evaluated in duplicate on 1% agaroseformaldehyde denaturing gels at 100 V for 5 h in 1× MOPS. Equivalent loading of RNA was corrected for by quantifying the ethidium bromide-stained 18S ribosomal RNA (Ntambi et al., 1996; Zhao et al., 1996) . The RNA was transferred to nylon-supported nitrocellulose membrane (NitroPure, Micron Separations Inc.) by capillary transfer overnight and was fixed by baking at 80°C.
Prehybridization was done for 1 h followed by an overnight hybridization carried out at 65°C in prewarmed prehybridization/hybridization solution (6× SSPE, .5% SDS, 5× Denhardt's solution). The hybridization solution also contained the probe reaction (1 × 10 6 cpm/mL) and yeast tRNA (GibcoBRL/Life Technologies). Membranes were washed in three 20-min, lowstringency washes (2× SSPE, .1% SDS) at room temperature followed by one 10-min, high-stringency wash (.1× SSC, .1% SDS) at 65°C. The membrane was then placed in an x-ray cassette with two intensifier screens and xray film (Kodak X-Omat AR, Rochester, NY) and exposed to the film at −70°C. The film was developed and the signals were quantified using an imaging densitometer (BioRad Laboratories, Mississauga, ON).
Milk fatty acid composition analysis was performed by A.V. Capuco (Liesman et al., 1995) , and the data were generously provided for this publication.
Statistical Analysis
Statistical significance for mRNA abundance was determined using the GLM procedure of SAS (1995) incorporating treatment, cow, and gel variances into the model. The error term was cow(treatment). The term y data referred to the data set and was assigned as the dependent variable. The model was defined as follows: model ydata = treatment cow(treatment) gel(treatment).
Results for LpL and SCD mRNA abundance were expressed as least squares means with SEM. The GLM was also used to analyze milk fatty acid composition and fat percentage along with the Student NeumanKeuls test using SAS (1995) . Three treatments and six blocks were incorporated into the model with a total of 18 observations.
Results and Discussion
Bovine growth hormone is recognized as the key hormone involved in the maintenance of lactation in ruminants (Bauman and Vernon, 1993) . The exact mechanism by which bGH exerts its action on the mammary gland is not clearly understood. Although mRNA for bGH receptors has been detected in the mammary gland (Glimm et al., 1990) , the ability of bGH to act directly on the mammary gland has not been conclusively demonstrated. Currently, IGF-I is implicated as an intermediary for bGH action on the mammary gland (Prosser et al., 1990) . This, along with the ability of bGH to enhance nutrient partitioning to the mammary gland, is believed to form the basis for the action of bGH in the bovine (Bauman and Currie, 1980) . Bovine growth hormone-releasing factor has increased milk production following its administration (Lapierre et al., 1988; Hodate et al., 1989) . Exogenous bGRF is believed to increase milk production through the stimulation of release of endogenous bGH from the pituitary gland. The elevated endogenous bGH levels result in an outcome similar to that caused by bGH treatment. Binelli et al. (1995) reported that, in the animals examined here, there was a significant increase in milk yield (P < .01) following bGH or bGRF treatment without an associated change in milk composition. Fatty acid composition analysis of milk from six blocks of animals examined in this experiment demonstrated a small, but significant, increase in C16:1 and C18:1 fatty acids due to bGH treatment but no effect from bGRF treatment (Table 1) . Previous studies by Lynch et al. (1992) and Apps et al. (1993) revealed that fatty acid profiles were unaltered by bGH treatment. Although the treated animals were mobilizing body reserves in this experiment, as shown by elevated serum NEFA concentration and reduced adipose tissue depots , there was no change in the total percentages of short-, medium-, or long-chain fatty acids in milk.
Milk fat percentage in the week prior to when the animals were slaughtered was not altered by either Table 1 . Fatty acid composition and fat percentage of milk from control cows (n = 6) and cows treated with bovine growth hormone (bGH, n = 6) or bovine growth hormone-releasing factor (bGRF, n = 6) bGH or bGRF treatment in the six blocks of animals examined here. Because milk yield was increased by both bGH and bGRF treatment, the total fat yield was increased. This led to the assumption that there would be an increase in de novo fatty acid synthesis and increased uptake of preformed fatty acids from the blood into the mammary gland, in order to meet the increased substrate requirements for milk fat synthesis. Our previous analysis of lipogenic enzymes (Beswick and Kennelly, 1998) suggests that de novo synthesis in the mammary gland is not altered by either bGH or bGRF treatment. Thus, the enhanced milk fat synthesis may in part be accounted for by increased mammary parenchymal weight per 100 kg of carcass weight and increased total RNA content of mammary tissue. This suggests that the total metabolism of the mammary gland was increased by the treatments. Although NEFA concentrations were also reported to be elevated by both treatments and fat depots were significantly reduced , there was not a proportional increase in long-chain fatty acids in the milk. The additional NEFA mobilized may have been utilized as an energy source or to satisfy the increased yield of longchain fatty acids in milk.
Lipoprotein Lipase
The delivery of preformed fatty acids to the mammary gland is accomplished through the action of LpL and the uptake of serum NEFA into the mammary gland. Lipoprotein lipase is synthesized in mammary alveolar epithelial cells during lactation and is transported to the capillary endothelium, where it is bound to the surface and activated (Scow and Chernick, 1987; Camps et al., 1990) . Lipoprotein lipase hydrolyzes the triglycerides transported in very-low-density lipoproteins (VLDL) and chylomicrons to yield monoglycerides and free fatty acids (Martin-Hidalgo et al., 1994) . These products are then taken up by the mammary gland via a concentration gradient that is created as the mammary gland converts the hydrolytic products into triglycer- ides within the tissue. Lipoprotein lipase is subject to both hormonal and metabolite control (Kirchgessner et al., 1989; Erskine et al., 1993) .
Northern blot analysis of the mRNA abundance of LpL in the mammary gland revealed that there was no significant difference between the treated and control animals. Neither bGH nor bGRF administration had any effect on the abundance of the 3.4-and 3.6-kb LpL transcripts in the mammary gland (Figure 1 ). Least squares means were 19.01, 20.28, and 12.75 OD × mm 2 for control and bGH-and bGRF-treated animals, respectively, and did not differ significantly (Table 2) . This result was supported by the findings of Liesman (1995) , who reported that the activity of LpL in tissue homogenates cultured from these experimental animals was unaltered by either treatment. From this we can conclude that the increased substrate did not come from increases in LpL mRNA abundance and activity in the mammary gland. These observations are further supported by Lough et al. (1989) and Azzara et al. (1987) , who also reported that bGH treatment did not increase LpL activity in the milk or mammary gland of dairy cows. Messenger RNA abundance of LpL in adipose tissue was reduced to 14.6 and 25.7% of that in control animals in bGH-and bGRF-treated animals, respectively. Both ) for control and bGH-, and bGRFtreated animals, respectively (Table 2) . Liesman et al. (1995) reported that LpL activity in omental fat homogenates from these animals was also reduced significantly by both treatments. The reduced mRNA abundance and activity of LpL in adipose tissue ensures that triglycerides carried by VLDL and chylomicrons are preferentially directed to the mammary gland for milk fat synthesis and not to adipose tissue for lipid storage. Control of LpL activity is complex and is determined by control at the level of transcription and translation as well as at the point at which LpL is transported to the capillary endothelium and activated (Kirchgessner et al., 1989; Erskine et al., 1993) . Growth hormone has been previously demonstrated in humans to act on LpL not at the transcription level, but rather at the translation or posttranslational level (Otosson et al., 1995) . Our results indicate that the effect of GH on adipose tissue in cattle is to directly reduce the expression of LpL. Growth hormone receptors exist in adipose tissue, and bGH is believed to exert its effects on LpL activity and lipogenesis in adipose tissue by inhibiting the effect of insulin (Etherton et al., 1987; Bauman and Vernon, 1993; Vernon et al., 1995) . Normally, in the absence of elevated GH, insulin stimulates LpL activity in adipose tissue. However, when GH is elevated during lactation and further by bGH and bGRF treatment, insulin does not stimulate adipose tissue lipogenesis. Insulin-like growth factor has also been demonstrated to increase LpL activity in human mammary gland (Kern et al., 1988; Kern et al., 1989) . Insulin-like growth factor I acts directly on IGF-I receptors in the mammary gland. Vanderkooi et al. (1995) reported that the animals in this study exhibited elevated IGF-I concentrations following bGH and bGRF treatments. Binelli et al. (1995) reported that the animals in this experiment had significantly (P < .01) elevated NEFA levels following bGH or bGRF administration. Free fatty acids are believed to negatively affect the concentration of LpL on the surface of capillary endothelium, thus negatively affecting LpL activity (Otosson et al., 1995) . It is possible that the elevated serum NEFA concentration associated with bGH and bGRF treatment attenuates the effects of elevated serum IGF-I concentration resulting from bGH and bGRF treatment.
Stearoyl-CoA Desaturase
Stearoyl-CoA desaturase exists in two forms, SCD1 and SCD2. Stearoyl-CoA desaturase I is the form found in the lactating mammary gland and adipose tissue. Three major proteins make up SCD: NADH-cytochrome b5 reductase, cytochrome b5, and the terminal desaturase. Through a transfer of electrons between these proteins, stearoyl-CoA (C18:0) and palmitoyl-CoA (C16:0) can be converted to oleoyl-CoA (C18:1) and palmitoleoylCoA (C16:1), respectively. This transfer of electrons enables animals to introduce ∆9 double bonds into these fatty acids.
The amount of unsaturated fatty acids present in milk fat has been previously demonstrated to be unaffected by bGH treatment in cattle (Lynch et al., 1992; Apps et al., 1993) . Fatty acid composition can be greatly influenced by energy balance. The treated animals in this study were apparently in negative energy balance because their adipose tissue was actively being mobilized with a net loss of fatty acids, although they were calculated to have been in positive energy balance . Binelli et al. (1995) accounted for this discrepancy by postulating that the NE l for the feed had been inaccurately calculated. Control animals were apparently in a positive energy balance because their adipose tissue was not undergoing lipolysis sufficient to produce a net loss of fatty acids. To measure the transcription level of SCD in the mammary gland mRNA, abundance was analyzed. Recombinant bGH had no significant effect on the abundance of the 4.9-kb SCD message in mammary gland (Figure 3) , nor was there a tendency for the SCD message to be reduced following bGH treatment. Bovine GRF reduced (P < .03) the abundance of the 4.9-kb SCD transcript. Least squares means of arbitrary densitometric units were found to be 11.29, 9.76, and 7.18 (OD × mm 2 ) for control, bGH, and bGRF, respectively (Table 3 ). The reduction in SCD message caused by bGRF treatment may account for the lack of increase in C16:1 and C18:1 fatty acids as compared to the controls. The amount of message relative to controls is reduced and the total metabolic activity of the mammary gland is increased by bGRF treatment , resulting in unchanged fatty acid composition. In the case of the bGH-treated animals, there was a significant increase in the percentage of C16:1 and C18:1 fatty acids. This was supported by the maintenance of ) in mammary gland (n = 6) and adipose tissue (n = 4) of control cows and cows treated with bovine growth hormone (bGH) or bovine growth hormone-releasing factor (bGRF) the synthesis of SCD message, as compared to the controls, as well as through the increased metabolism of the mammary gland reported by Binelli et al. (1995) . The net result is a modest, though significant, increase in milk unsaturated fatty acids.
The 4.9-kb message of the SCD gene in adipose tissue was reduced below the level of detection by both bGH and bGRF (Figure 4) (Table 3 ). The least squares means of mRNA abundance of the control animals was 14.16 OD × mm 2 . The absence of detectable SCD message for bGH and bGRF treatments suggests that the activity is also reduced in adipose tissue, although this was not determined. Insulin increases the concentration of SCD mRNA in nonruminants as well as its activity in adipose tissue (Cook, 1991; Ntambi, 1995) . Growth hormone suppresses the ability of insulin to stimulate adipose tissue metabolism (Bauman and Vernon, 1993) . Growth hormone likely exerts its action on SCD activity and expression by counteracting the stimulatory effect of insulin and perhaps by directly down-regulating transcription and activity of SCD. There has been no evidence presented in literature on the ability of bGH and bGRF to influence SCD synthesis and activity directly, but GH is known to act on adipose tissue directly.
The reduction in SCD and LpL mRNA abundance associated with reduced fatty acid synthase and acetylCoA carboxylase mRNA and protein abundance (Beswick and Kennelly, 1998) in adipose tissue and elevated NEFA levels in serum ensure enhanced delivery of nutrients to the mammary gland. Along with the changes in the mammary gland RNA and DNA content and parenchymal weight , fatty acid composition of triglycerides remains relatively unaltered by either treatment.
Implications
Information from this study of these effects of bovine growth hormone (bGH) and bovine GH-releasing factor (bGRF) treatment on lipoprotein lipase and stearoylCoA desaturase (SCD) messenger RNA in mammary gland and adipose tissue provides new insights into the regulation of fatty acid uptake and desaturation and increases our understanding of the regulation of fat metabolism in cattle. Bovine GH and bGRF seem to have little impact on the expression of SCD and lipoprotein lipase in mammary gland. This coupled with the results from adipose tissue documents the role of bGH and bGRF in the regulation of fat metabolism. This information should facilitate the elucidation of factors involved in the regulation of lipid synthesis in lactating dairy cows.
